Palvella Therapeutics公布Qtorin™ 3.9%无水雷帕霉素凝胶(Qtorin™ Rapamycin)治疗皮肤静脉畸形的二期Toiva临床试验积极顶线结果。这是一种严重的罕见遗传疾病,目前尚无FDA批准的治疗方案。
Palvella Therapeutics公布Qtorin™ 3.9%无水雷帕霉素凝胶(Qtorin™ Rapamycin)治疗皮肤静脉畸形的二期Toiva临床试验积极顶线结果。这是一种严重的罕见遗传疾病,目前尚无FDA批准的治疗方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.